Cutaneous DNA Vaccination Against Ebola Virus by Particle Bombardment: Histopathology and Alteration of CD3-positive Dendritic Epidermal Cells

2001 ◽  
Vol 38 (2) ◽  
pp. 203-215 ◽  
Author(s):  
K. E. Steele ◽  
K. Stabler ◽  
L. VanderZanden

We analyzed the localization of gold particles, expression of immunogenic protein, and histopathologic changes after vaccinating guinea pigs and mice with a DNA vaccine to the Ebola virus glycoprotein administered by cutaneous particle bombardment. Gold particles were deposited in all layers of the epidermis and in the dermis. Those in the epidermis were lost as the damaged layers sloughed, while those in the dermis were phagocytized by macrophages. Glycoprotein was demonstrated by immunohistochemistry primarily in keratinocytes in the epidermis and hair follicle epithelium and less frequently in dermal macrophages, fibroblasts, sebocytes, and cells that appeared to be Langerhans cells. The number of cells that expressed glycoprotein increased between 4 and 8 hours postvaccination, then decreased to near zero by 48 hours. The vaccine sites were histologically divisible into three zones. The central portion, zone 1, contained the most gold particles in the dermis and epidermis and had extensive tissue damage, including full-thickness epidermal necrosis. Zone 2 contained fewer gold particles in the epidermis and dermis and had less extensive necrosis. The majority of cells in which glycoprotein was expressed were in zone 2. Zone 3 contained gold particles only in the epidermis and had necrosis of only a few scattered cells. Regeneration of the epidermis in damaged areas was evident at 24 hours postvaccination and was essentially complete by day 5 in the mice and day 10 in the guinea pigs. Inflammatory changes were characterized by hemorrhage, edema, and infiltrates of neutrophils initially and by infiltrates of lymphocytes and macrophages at later times. In zone 1, inflammation affected both the epidermis and dermis. Peripherally, inflammation was relatively limited to the epidermis. CD3-positive dendritic epidermal cells were demonstrated in the epidermis and superficial hair follicles of unvaccinated immunocompetent mice and beige mice but not of SCID mice. These cells disappeared from all but the most peripheral portions of the vaccine sites of vaccinated mice within 24 hours. They reappeared slowly, failing to reach numbers comparable with unvaccinated mice by 35 days postvaccination. The epidermis of control guinea pigs also had CD3-positive cells, but they did not have dendrites. These findings should contribute to a better understanding of the mechanisms operating in response to DNA vaccination by particle bombardment.

Virology ◽  
1998 ◽  
Vol 250 (1) ◽  
pp. 230-240 ◽  
Author(s):  
Anthony H.-C. Choi ◽  
Mitali Basu ◽  
Mary N. Rae ◽  
Monica M. McNeal ◽  
Richard L. Ward

Viruses ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 987 ◽  
Author(s):  
Mable Chan ◽  
Anders Leung ◽  
Bryan D. Griffin ◽  
Robert Vendramelli ◽  
Nikesh Tailor ◽  
...  

Ebola virus (EBOV) is a zoonotic pathogen that poses a significant threat to public health, causing sporadic yet devastating outbreaks that have the potential to spread worldwide, as demonstrated during the 2013–2016 West African outbreak. Mouse models of infection are important tools for the development of therapeutics and vaccines. Exposure of immunocompetent mice to clinical isolates of EBOV is nonlethal; consequently, EBOV requires prior adaptation in mice to cause lethal disease. Until now, the only immunocompetent EBOV mouse model was based on the Mayinga variant, which was isolated in 1976. Here, we generated a novel mouse-adapted (MA)-EBOV based on the 2014 Makona isolate by inserting EBOV/Mayinga-MA mutations into the EBOV/Makona genome, followed by serial passaging of the rescued virus in suckling mice. The resulting EBOV/Makona-MA causes lethal disease in adult immunocompetent mice within 6 to 9 days and has a lethal dose (LD50) of 0.004 plaque forming units (PFU). Two additional mutations emerged after mouse-adaptation in the viral nucleoprotein (NP) and membrane-associated protein VP24. Using reverse genetics, we found the VP24 mutation to be critical for EBOV/Makona-MA virulence. EBOV/Makona-MA infected mice that presented with viremia, high viral burden in organs, increased release of pro-inflammatory cytokines/chemokines, and lymphopenia. Our mouse model will help advance pre-clinical development of countermeasures against contemporary EBOV variants.


1999 ◽  
Vol 179 (s1) ◽  
pp. S203-S217 ◽  
Author(s):  
Brett M. Connolly ◽  
Keith E. Steele ◽  
Kelly J. Davis ◽  
Thomas W. Geisbert ◽  
Wayne M. Kell ◽  
...  

2016 ◽  
Vol 214 (suppl 3) ◽  
pp. S326-S332 ◽  
Author(s):  
Shipo Wu ◽  
Andrea Kroeker ◽  
Gary Wong ◽  
Shihua He ◽  
Lihua Hou ◽  
...  

2012 ◽  
Vol 14 (5) ◽  
pp. 348-352 ◽  
Author(s):  
Kotla S. Reddy ◽  
Brabhi R. Rashmi ◽  
Hosur J. Dechamma ◽  
Susarla Gopalakrishna ◽  
N. Banumathi ◽  
...  

2015 ◽  
Vol 212 (suppl 2) ◽  
pp. S242-S246 ◽  
Author(s):  
Thomas Hoenen ◽  
Andrea Marzi ◽  
Dana P. Scott ◽  
Friederike Feldmann ◽  
Julie Callison ◽  
...  
Keyword(s):  

2006 ◽  
Vol 193 (12) ◽  
pp. 1650-1657 ◽  
Author(s):  
Thomas W. Geisbert ◽  
Lisa E. Hensley ◽  
Elliott Kagan ◽  
Erik Zhaoying Yu ◽  
Joan B. Geisbert ◽  
...  

2003 ◽  
Vol 92 (2) ◽  
pp. 187-193 ◽  
Author(s):  
Jenny L. Mellquist-Riemenschneider ◽  
Aura R. Garrison ◽  
Joan B. Geisbert ◽  
Kamal U. Saikh ◽  
Kelli D. Heidebrink ◽  
...  

2020 ◽  
Vol 94 (8) ◽  
Author(s):  
Xue Zhang ◽  
Tingting Zhang ◽  
John N. Davis ◽  
Andrea Marzi ◽  
Anthony M. Marchese ◽  
...  

ABSTRACT Given that the Ebola virus (EBOV) infects a wide array of organs and cells yet displays a relative lack of neurotropism, we asked whether a chimeric vesicular stomatitis virus (VSV) expressing the EBOV glycoprotein (GP) might selectively target brain tumors. The mucin-like domain (MLD) of the EBOV GP may enhance virus immune system evasion. Here, we compared chimeric VSVs in which EBOV GP replaces the VSV glycoprotein, thereby reducing the neurotoxicity associated with wild-type VSV. A chimeric VSV expressing the full-length EBOV GP (VSV-EBOV) containing the MLD was substantially more effective and safer than a parallel construct with an EBOV GP lacking the MLD (VSV-EBOVΔMLD). One-step growth, reverse transcription-quantitative PCR, and Western blotting assessments showed that VSV-EBOVΔMLD produced substantially more progeny faster than VSV-EBOV. Using immunodeficient SCID mice, we focused on targeting human brain tumors with these VSV-EBOVs. Similar to the findings of our previous study in which we used an attenuated VSV-EBOV with no MLD that expressed green fluorescent protein (GFP) (VSV-EBOVΔMLD-GFP), VSV-EBOVΔMLD without GFP targeted glioma but yielded only a modest extension of survival. In contrast, VSV-EBOV containing the MLD showed substantially better targeting and elimination of brain tumors after intravenous delivery and increased the survival of brain tumor-bearing mice. Despite the apparent destruction of most tumor cells by VSV-EBOVΔMLD, the virus remained active within the SCID mouse brain and showed widespread infection of normal brain cells. In contrast, VSV-EBOV eliminated the tumors and showed relatively little infection of normal brain cells. Parallel experiments with direct intracranial virus infection generated similar results. Neither VSV-EBOV nor VSV-EBOVΔMLD showed substantive infection of the brains of normal immunocompetent mice. IMPORTANCE The Ebola virus glycoprotein contains a mucin-like domain which may play a role in immune evasion. Chimeric vesicular stomatitis viruses with the EBOV glycoprotein substituted for the VSV glycoprotein show greater safety and efficacy in targeting brain tumors in immunodeficient mice when the MLD was expressed within the EBOV glycoprotein than when EBOV lacked the mucin-like domain.


Sign in / Sign up

Export Citation Format

Share Document